The combination of MEK and PIK3CA/mTOR inhibitors in various concentrations inhibits the growth of several GC cells by reducing the level of AKT, p-AKT, MAP, p-MAP, 4E-BP1, and p-4EBP1 [216]. The gene discussed is PIK3CA; the disease is gastric cancer.